일회용 혈액백 시장 : 제품 유형별, 재질별, 구성별, 용도별, 최종 사용자별 예측(2026-2032년)

The Single Use Blood Bag Market was valued at USD 1.96 billion in 2025 and is projected to grow to USD 2.07 billion in 2026, with a CAGR of 6.57%, reaching USD 3.06 billion by 2032.

A concise but strategic introduction to single-use blood bag technologies, clinical imperatives, regulatory forces, and procurement priorities shaping provider decisions

This executive summary introduces the single-use blood bag sector by outlining the clinical imperatives, material science advances, and procurement priorities that currently steer purchasing decisions across healthcare systems. Over the past decade, clinicians and supply chain leaders have elevated priorities such as biocompatibility, pathogen mitigation, and handling ergonomics, which in turn influence product selection and supplier evaluations. Inflationary pressures on raw materials and logistical complexity have converged with clinical initiatives to reduce transfusion-related risks, creating a procurement environment that prizes traceability and validated quality controls.

As hospitals and blood services refine inventory management and regulatory compliance, single-use blood bag design and supplier credentials carry increased weight. Technological enhancements that reduce hemolysis, improve additive stability, and enable pathogen-reduction workflows are becoming differentiators rather than optional features. Consequently, procurement teams must balance unit cost with lifecycle performance, clinical outcomes, and vendor reliability. This introduction frames the subsequent analysis by highlighting how clinical needs, regulatory expectations, and operational realities combine to shape both short-term sourcing choices and longer-term strategic shifts in the sector.

Analytical overview of transformative shifts in single-use blood bag landscape including material innovations, pathogen-reduction trends, and supply chain resilience drivers

The landscape for single-use blood bags is undergoing transformative shifts driven by materials innovation, pathogen-reduction adoption, and a reorientation of global supply chains toward resilience. Advances in non-PVC polymer science and alternative sealing technologies have reduced concerns around plasticizers and enabled hospitals to meet stricter biocompatibility standards. Concurrently, pathogen-reduction systems and improvements in leukoreduction techniques have elevated requirements for bag compatibility, prompting manufacturers and contract producers to redesign fluid contact surfaces and tubing geometries.

Supply chain dynamics have also shifted: manufacturers increasingly pursue dual-source strategies, regionalized manufacturing, and qualified second-tier suppliers to mitigate geopolitical and logistical risk. Regulatory agencies are iterating guidance that tightens sterilization validation and material traceability, which in turn encourages investment in serialization and batch-level analytics. These convergent trends are reshaping product roadmaps and procurement evaluation criteria, so purchasers now evaluate not only unit performance but also supplier geography, quality infrastructure, and near-term capacity commitments when making sourcing decisions.

In-depth assessment of the cumulative effects of recent and pending United States tariffs on single-use blood bag supply chains, sourcing strategies, and clinical procurement

The cumulative impact of United States tariff actions implemented in 2025 has introduced new complexity to sourcing strategies for single-use blood bag components and finished goods. Tariffs on imported polymers, specialized tubing, and certain manufacturing equipment have increased landed costs for suppliers that rely on cross-border inputs, pushing many to reassess their supplier base and consider nearshoring or onshoring as risk mitigation. Procurement teams are responding by seeking longer-term agreements with tier-one suppliers and by incorporating tariff pass-through scenarios into contract negotiations.

Operationally, higher import duties have shortened planning horizons for distributors and hospitals, prompting some organizations to extend inventory horizons or qualify additional local manufacturers. In parallel, suppliers with diversified manufacturing footprints and in-region extrusion and assembly capabilities have gained negotiating leverage, enabling them to offer more stable lead times despite higher nominal costs. Policy uncertainty has also driven interest in tariff-minimizing strategies such as component substitution, redesign to use domestically available materials, and greater reliance on bonded warehousing to smooth cash flow implications. Ultimately, the tariffs have accelerated a broader shift toward supply chain diversification and increased emphasis on supplier transparency and compliance.

Segment-focused insights across product types, materials, configurations, end users, and applications that clarify clinical needs and procurement pathways in detail

Segmentation analysis reveals nuanced differences in clinical needs, manufacturing complexity, and procurement priorities across product types, materials, configurations, end users, and applications. Product type segmentation includes Plasma Bags, Platelet Bags, Red Cell Bags, Specialized Application Bags, and Whole Blood Bags; Plasma Bags are offered in 250 milliliter, 300 milliliter, and 500 milliliter formats, Platelet Bags are distinguished by pathogen reduction versus standard designs, Red Cell Bags separate leukoreduced from non-leukoreduced options, and Whole Blood Bags include CP2D, CPD, and CPDA-1 formulations. These distinctions drive distinct validation requirements, additive compatibility tests, and storage profile expectations.

Material type segmentation differentiates non-PVC and PVC constructions, with non-PVC options further divided into polyolefin and silicone-based materials. Each material pathway presents trade-offs in terms of elasticity, leachables profile, and weldability that influence both clinical handling and sterilization validation. Configuration segmentation covers double bag, quadruple bag, single bag, and triple bag systems, where additional bags enable more complex collection and processing workflows but increase manufacturing and sterilization complexity. End user segmentation spans blood banks, clinics, diagnostic centers, and hospitals, with blood banks further categorized as private or public institutions, each with distinct procurement cycles and inventory management paradigms. Finally, application segmentation encompasses blood collection, blood storage, and blood transfusion, with transfusion workflows subdivided into emergency transfusion and routine transfusion pathways. Understanding these layered segments is critical for tailoring product specifications, qualifying suppliers, and aligning inventory policies with clinical workflows.

Regional intelligence revealing demand dynamics, regulatory variations, and supply chain strengths across Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics shape regulatory expectations, supplier concentration, and sourcing strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific regions. In the Americas, procurement emphasizes rapid response, regional manufacturing partnerships, and alignment with clinical networks that prioritize pathogen mitigation and traceability. Payment models and hospital group purchasing organizations influence contract structures and the degree to which total cost of ownership considerations drive adoption of premium features.

In Europe, Middle East & Africa, the regulatory environment and national blood service models create heterogeneity in approval pathways and product acceptance. Manufacturers targeting this region prioritize conformity with regional regulatory frameworks, extended shelf-life validation, and compatibility with diverse additive systems. In the Asia-Pacific region, rapid healthcare expansion and localized manufacturing capacity are producing both opportunity and competition. Demand growth in emerging markets is accelerating interest in cost-efficient configurations and modular bag systems suitable for decentralized blood collection, while advanced markets in the region prioritize compatibility with high-throughput automated processing equipment. Taken together, regional variations underscore the need for differentiated go-to-market strategies and local regulatory expertise.

Competitive landscape and company-level insights focusing on product portfolios, strategic partnerships, manufacturing footprints, and innovation trajectories in the sector

Company-level positioning within the single-use blood bag sector centers on product portfolio breadth, manufacturing footprint, partnership models, and innovation investment. Leading manufacturers are extending portfolios to support pathogen-reduction compatibility, enhanced additive stabilization, and alternative-material options that address regulatory concerns about plasticizers and extractables. Strategic partnerships with sterilization providers, extrusion specialists, and contract manufacturers enable faster scale-up while preserving capital efficiency.

Manufacturers with vertically integrated operations or regional assembly hubs have demonstrated advantages in lead-time reliability and tariff exposure management. At the same time, contract manufacturing organizations play a pivotal role in enabling new entrants and niche product developers to achieve regulatory compliance and production scale. Companies are also differentiating through enhanced quality management systems, investment in serialization and batch analytics, and clinical evidence generation that validates handling and performance claims. These competitive dynamics favor organizations that can combine robust quality infrastructure with flexible manufacturing capacity and targeted clinical support services.

Practical and prioritized recommendations for industry leaders to optimize sourcing, strengthen quality controls, and accelerate adoption of single-use blood bag technologies

Industry leaders should prioritize a set of actionable measures to fortify supply chains, accelerate clinically meaningful innovation, and align procurement decisions with long-term operational resilience. First, strengthen supplier diversification by qualifying multiple manufacturing sources across different geographies and validating second-source components to reduce single points of failure. Next, invest in materials and design validation that anticipate regulatory attention to leachables, biocompatibility, and sterilization traceability, while also demonstrating clinical benefit through targeted usability and hemocompatibility studies.

Further, adopt procurement practices that balance unit price with lifecycle costs by factoring in sterilization, storage, and clinical performance metrics. Build contractual flexibility with indexed pricing clauses or shared escalation mechanisms to absorb short-term tariff impacts while preserving supplier relationships. Enhance digital traceability through batch serialization and integrate quality analytics into supplier scorecards to enable proactive corrective actions. Finally, accelerate collaboration between clinical teams, blood services, and purchasing groups to pilot new configurations-such as pathogen-reduction-compatible platelet systems or non-PVC whole blood bags-in controlled settings prior to broad rollouts. These combined actions will drive measurable improvements in supply assurance and clinical outcome alignment.

Transparent research methodology explaining data sources, validation techniques, stakeholder interviews, and analytical frameworks used to ensure robustness and reproducibility

The research methodology underpinning this executive summary integrates primary stakeholder interviews, technical literature review, regulatory guidance analysis, and supply chain mapping to ensure robust, reproducible conclusions. Primary inputs include structured interviews with procurement leaders, blood bank directors, clinical transfusion experts, and manufacturing operations managers, which provided insight into purchasing cycles, validation requirements, and lead-time sensitivities. Secondary inputs encompass peer-reviewed clinical research, material safety data, device regulatory filings, and publicly available manufacturing standards that informed technical assessments of material and design trade-offs.

Analytical techniques included component-level risk assessment, scenario analysis for policy impacts, and triangulation of supplier capabilities with regional regulatory constraints. Data quality controls featured source triangulation, methodological transparency, and audit trails for interview transcripts and analytical assumptions. Wherever possible, findings were validated through cross-functional stakeholder review to ensure practical relevance and to reduce confirmation bias. This layered approach produces an evidence-based synthesis that balances clinical, regulatory, and operational perspectives.

Conclusive synthesis of core findings, strategic implications, and the evolving clinical and supply chain considerations that will influence procurement and innovation paths

This conclusion synthesizes the most salient strategic implications for purchasers, manufacturers, and policy stakeholders within the single-use blood bag ecosystem. The sector is being reshaped by material innovation, heightened pathogen-reduction imperatives, and supply chain realignment in response to policy and tariff pressures. Procurement organizations must therefore adopt more holistic evaluation frameworks that weigh clinical compatibility, lifecycle performance, supplier resilience, and compliance readiness in equal measure.

Manufacturers and contract producers that invest in validated alternative materials, regional capacity, and integrated quality data systems will be better positioned to meet evolving clinical and regulatory expectations. Simultaneously, coordinated planning between clinical services and supply chain teams can accelerate safe adoption of improved bag configurations while minimizing disruption to transfusion workflows. In short, resilience and clinical alignment-supported by rigorous supplier qualification and transparent traceability-will determine which strategies deliver sustainable competitive advantage in the years ahead.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Single Use Blood Bag Market, by Product Type

• 8.1. Plasma Bags
  • 8.1.1. 250 Milliliter
  • 8.1.2. 300 Milliliter
  • 8.1.3. 500 Milliliter
• 8.2. Platelet Bags
  • 8.2.1. Pathogen Reduction
  • 8.2.2. Standard
• 8.3. Red Cell Bags
  • 8.3.1. Leukoreduced
  • 8.3.2. Non-Leukoreduced
• 8.4. Specialized Application Bags
• 8.5. Whole Blood Bags
  • 8.5.1. Cp2d
  • 8.5.2. Cpd
  • 8.5.3. Cpda-1

9. Single Use Blood Bag Market, by Material Type

• 9.1. Non-Pvc
  • 9.1.1. Polyolefin
  • 9.1.2. Silicone
• 9.2. Pvc

10. Single Use Blood Bag Market, by Configuration

• 10.1. Double Bag
• 10.2. Quadruple Bag
• 10.3. Single Bag
• 10.4. Triple Bag

11. Single Use Blood Bag Market, by Application

• 11.1. Blood Collection
• 11.2. Blood Storage
• 11.3. Blood Transfusion
  • 11.3.1. Emergency Transfusion
  • 11.3.2. Routine Transfusion

12. Single Use Blood Bag Market, by End User

• 12.1. Blood Banks
  • 12.1.1. Private
  • 12.1.2. Public
• 12.2. Clinics
• 12.3. Diagnostic Centers
• 12.4. Hospitals

13. Single Use Blood Bag Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Single Use Blood Bag Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Single Use Blood Bag Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Single Use Blood Bag Market

17. China Single Use Blood Bag Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. 3S Corporation
• 18.6. B.L. Life Sciences Pvt. Ltd.
• 18.7. Becton, Dickinson and Company
• 18.8. Biolife Plasma Services, L.P.
• 18.9. Bionic Medizintechnik GmbH
• 18.10. Blue Neem Medical Devices Ltd.
• 18.11. C.Y. Medical Co., Ltd.
• 18.12. Demophorius Healthcare
• 18.13. ERENLER MEDIKAL
• 18.14. Fresenius Kabi AG
• 18.15. General Cooperation Industry Co., Ltd.
• 18.16. Grifols, S.A.
• 18.17. Haemonetics Corporation
• 18.18. HLL Lifecare Limited
• 18.19. J. Mitra & Co. Pvt. Ltd.
• 18.20. Kawasumi Laboratories, Inc.
• 18.21. Lifecare Medical Innovation
• 18.22. Maco Pharma S.A.S.
• 18.23. Mitra Industries Pvt. Ltd.
• 18.24. Mohini Health & Hygiene Ltd.
• 18.25. QED Kares Packers Pvt. Ltd.